OncoMatch/Clinical Trials/NCT06094101

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

Is NCT06094101 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Peptide vaccine IPX for ewing sarcoma.

Phase 1/2RecruitingUniversity Hospital TuebingenNCT06094101Data as of May 2026

Treatment: Peptide vaccine IPX — The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine. Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Rhabdomyosarcoma

Disease stage

Metastatic disease required

Prior therapy

Must have received: cytotoxic chemotherapy — intensive standard chemotherapy protocols

intensive standard chemotherapy protocols

Must have received: local therapy — all remaining tumor residua including all metastases have received local therapy (surgical removal or local irradiation)

all remaining tumor residua including all metastases have received local therapy by this time point: Either surgical removal or local irradiation

Must have received: adjuvant and/or maintenance cytotoxic treatment — completed

adjuvant and/or maintenance cytotoxic treatment ... has been completed

Cannot have received: haematopoietic stem cell transplantation

Subjects with a prior haematopoietic stem cell transplantation

Cannot have received: organ transplantation

prior organ transplantation

Lab requirements

Kidney function

Creatinine-clearance < 40ml/min

Liver function

Bilirubin > 4mg/dl; ALT > 400 U/l and/or AST > 400 U/l

Cardiac function

Ejection fraction < 25%

Ejection fraction < 25%; Creatinine-clearance < 40ml/min; Bilirubin > 4mg/dl; ALT > 400 U/l and/or AST > 400 U/l

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify